Servier Summer Interns Share Their Experiences
Discover our news
Servier Affirms Commitment to Cancer by Announcing the Opening of a Global R&D Center and Expanded Offices in Boston’s Seaport
Servier Statement on U.S. Supreme Court Overturning Roe v. Wade
Reaching New Heights Through the Climb to Fight Cancer Expedition
Servier to Showcase Growing Oncology Portfolio at the ASCO and EHA 2022 Annual Meetings
Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia
Overcoming the Medical Industry’s Supply Chain Challenges
Phase 3 AGILE Data of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia Published in the New England Journal of Medicine
Servier Joins Everest Climb to Fight Cancer Benefitting Fred Hutchinson Cancer Research Center